$0.700
-0.088 (-12.50%)收盤時
- 最高
- 0.810
- 開盤
- 0.810
- 成交量加權均價
- 0.72
- 成交量
- 330.01K
- 市值
- 2.79M
- 最低
- 0.646
- 成交金額
- 237.18K
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 0.00
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
AI 分析 of Virax Biolabs Group Ltd (VRAX)
賣出VRAX is not a good buy right now due to its extremely low RSI of 19.69, indicating oversold conditions, and a staggering year-to-date change of -91.67%. The stock has also experienced a 5-day decline of 33.88%, suggesting a strong downward momentum. The main risk is its gross margin of -3381.20%, indicating severe profitability issues that could deter long-term investors.
估值指標
事件時間軸
資訊
7.510-29PRnewswireVirax Signs Distributor Agreements in China to Expand Market Reach
7.510-29NewsfilterVirax Biolabs Appoints Three Distributors for ImmuneSelect in China
2.010-06stocktwitsRussian Plague Scare Triggers Vaccine Stock Surge
2.007-17NASDAQ.COMCareDx Soars 35% After Medicare Coverage Finalization
9.507-16PRnewswireVirax Biolabs Releases Fiscal 2026 Annual Report and Updates
VRAX 常見問題 —— 由 Alphio AI 解答
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1). It operates in the Healthcare sector (IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES industry).
VRAX is not a good buy right now due to its extremely low RSI of 19.69, indicating oversold conditions, and a staggering year-to-date change of -91.67%. The stock has also experienced a 5-day decline of 33.88%, suggesting a strong downward momentum. The main risk is its gross margin of -3381.20%, indicating severe profitability issues that could deter long-term investors.
社群
更多 ↗暫無貼文
註冊或登入後參與討論相關文章
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。